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Abstract
Background: Alzheimer’s disease (AD) is the most common type of dementia. International multilateral cost-of-illness
(COI) studies have revealed that the cost of treating this disease is huge, which places a significant burden on patients’
families and their healthcare systems. However, no such studies have been conducted in China. This study estimates
the monetary costs of patients with AD in mainland China.
Methods: This study planned to start in October 2015 and to finish in March 2016. It covered 30 provincial,
municipal, and autonomous regions in mainland China. The sites and research centres in each region were
selected randomly. The participating sites include Tier 3 hospitals, psychiatric hospitals, geriatric hospitals, nursing homes,
and residences. More than 2500 patients with AD and their caregivers from all of the 81 research centres will be enrolled
to fulfil the calculated sample size. The monetary costs of AD, which include direct medical costs, direct non-medical
costs, and indirect costs, are being collected using the electronic medical record system and residence health
system at each site; face-to-face interviews are being performed when necessary. Descriptive statistics will be
used to summarise the patient characteristics and generalised linear models will be developed to calculate the costs.
Results: The main findings will include national and per patient annual monetary costs of AD in China.
Conclusions: To the best of our knowledge, this is the first large-scale cluster-randomized observational study
to estimate the economic burden of AD in Chinese patients. The methodology used was based on China’s
current healthcare system and is suitable for the purpose of the study. Because the burden of AD on patients,
families, healthcare providers, and society is substantial and increasing, it is important and necessary to understand the
economic burden caused by this disease.
Trial registration: Our trial was retrospectively registered on ClinicalTrials.gov, NCT02694445, registered on 02/26/2016
Keywords: Alzheimer’s, Dementia, Cost of illness, Healthcare cost, Observational study
Background
The Chinese population is rapidly aging. The sixth
national population census showed that there were 178
million people aged ≥ 60 years in China, accounting for
13.26% of the total population [1]. The incidence of senile
dementia (age of onset ≥65 years) is ~6%, with Alzheimer’s
disease (AD) being the most common form, accounting
for ~65% of cases [2–5]. In 2014, an epidemiological study
that encompassed 30 cities/towns and 45 rural areas from
5 representative Chinese provinces demonstrated that the
incidence of dementia and AD in people aged ≥65 was
5.14 and 3.21%, respectively. Furthermore, the prevalence
was significantly higher in rural areas compared to urban
populations [6].
The monetary costs of AD have been studied worldwide.
International multilateral cost-of-illness (COI) studies can
identify and measure all of the costs associated with any
specific disease including the direct, indirect, and intan-
gible costs; [7] such studies were designed to provide an
estimate of the economic burden of disease [7]. A recent
study indicated that the cost of AD is substantial and
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increases with disease severity [8]. Between 2009 and
2010, a cross-sectional survey conducted in the United
Kingdom, which included 249 AD patients from 18 cities,
revealed that the total monetary costs of AD were ~ £4000
per citizen every 3 months [9]. Moreover, the annual costs
associated with AD were $100 billion in the United States,
of which $24.6 billion was for healthcare (including care-
giver burden and the cost of medical care) [10]. In 2014, a
French study showed that the average total monthly costs
of AD were €2450 using the proxy good method, and
€3102 using the opportunity cost method [11]. In the
same year, a study in Finland indicated that the medical
costs of an AD patient were €23,059 per person per year
[12]. Thus, AD creates a heavy burden to both patients’
families and society and is also a huge challenge to eco-
nomic development and elderly healthcare. However, to
date, studies on the monetary costs of AD have mostly
been performed in developed countries such as the United
States and United Kingdom, and there have been no
large-scale national surveys on the economic burden
caused by this disease in developing countries such as
China. Because the burden of AD on patients, families,
healthcare providers, and society is substantial and
increasing [13, 14], our large-scale national study in China
is important and necessary.
Methods
Study design
This study is a multicentre study with a large sample
size that began in October 2015. Before beginning the
study, the protocol and case report form (CRF) were
designed using an operator manual, and advice was
sought from international scholars. The study design
and procedures are illustrated in Fig. 1.
Distribution of investigation sites and inclusion criteria
This study covered 30 provincial, municipal, and autono-
mous regions in mainland China, with the exception of
Tibet, Hong Kong, and Macao. The target sites included
Tier 3 hospitals, mental health centres/psychiatric hospitals,
gerontology hospitals, nursing homes/gerocomiums/care
facilities, and both urban and rural residences. The study
sites in each region were selected randomly. However, each
site must meet the following pre-specified criteria: (1) Tier
3 general hospitals, mental health centres, psychiatric




1. Randomly select research centres for all 30 provincial, municipal, and 
autonomous regions in China (n1=81).
2. Determine the total required number of patients diagnosed with AD 
necessary for statistically significant results (n2 2500).
3. Pre-specify the proportion of outpatients, inpatients, nursing home subjects, 
and residences for each participating site based on our pilot study.
4. Provide unified training for investigators.
1. Collect information from electronic medical records and residence health 
information management systems.
2. Complete the questionnaires using face-to-face interviews.
3. Quality control and feedback.
1. Summarise the monetary cost of AD.
2. Describe and analyse the results of AD burden in China.
Fig. 1 Flow chart of the monetary costs of Alzheimer’s disease in China. Note: n1, the number of research centres; n2, the number of patients
with AD
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dementia specialists, psychological evaluation divisions,
AD-relevant diagnostic equipment (e.g., computed tomog-
raphy [CT], 1.5 T or above magnetic resonance imaging
[MRI]), and laboratories with the ability to examine samples
that may aid in the diagnosis of AD. (2) Nursing homes/
gerocomium/care facilities with dementia specialists, >100
beds, and the ability to admit patients with AD. (3) Resi-
dences with >500 residents, a residence health system (e.g.,
electronic health records), active resident or village com-
mittees, and staff who can assist with the study. (4) Patients
who fully understand the protocol and agree to participate
in the study.
The study included 81 research centres that meet the
inclusion criteria (Fig. 2).
Criteria for AD patients
Because we investigate the direct and indirect monetary
costs of AD, strict inclusion and exclusion criteria for AD
are essential. The following patients are being included:
those who are newly diagnosed with AD in this study or
who have been previously diagnosed, patients aged ≥
60 years with normal or corrected vision and hearing, and
those who are able to provide an informed consent form
signed by himself/herself or a legal guardian. Dementia is
diagnosed according to the criteria described by the Diag-
nostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR) [15]. The diagnosis
of AD is made using the National Institute of Neurologic
and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) [16]. The diagnosis also required
to meet the following: a Modified Hachinski Ischemic
Scale (MHIS) score ≤ 4 [17], an Activity of Daily Living
Scale (ADL) score ≥ 23 [18], and a Geriatric Depres-
sion Scale (GDS) score < 11 [19]. Neuroimaging MRI
is used to support the AD diagnosis (atrophy in the
medial temporal lobe and a white matter lesion score ≤ 2
according to the Fazekas criteria) [20, 21]. The severity of
AD is estimated according to the mini-mental state exam-
ination (MMSE) scale [22] (for illiterate dementia mild,
21–24 points; moderate, 11–20; severe, ≤10. For literate
dementia: mild, 16–19 points; moderate, 8–15; severe,
≤7). The diagnosis of AD is confirmed by brain CT or
MRI scans and laboratory tests to rule out any significant
Fig. 2 The distribution of investigational centres in China. Notes: 01, Anhui Province; 02, Beijing City; 03, Fujian Province; 04, Gansu Province; 05,
Guangdong Province; 06, Guangxi Autonomous; 07, Guizhou Province; 08, Hainan Province; 09, Hebei Province; 10, Henan Province; 11, Heilongjiang
Province; 12, Hubei Province; 13, Hunan Province; 14, Jilin Province; 15, Jiangsu Province; 16, Jiangxi Province; 17, Liaoning Province; 18, Inner Mongolia
Autonomous; 19, Qinghai Province; 20 Shandong Province; 21, Shanxi Province; 22, Shaanxi Province; 23, Shanghai City; 24, Sichuan Province; 25, Tianjin
City; 26, Xinjiang Autonomous; 27, Yunnan Province; 28, Zhejiang Province; 29, Chongqing City; 30, Ningxia Autonomous
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comorbidities. Patients will be excluded if they meet any
of the following criteria: presence of vascular dementia or
dementia caused by other factors such as major depres-
sion or other major psychiatric illnesses, thyroid dysfunc-
tion, encephalitis, multiple sclerosis and other dementias
such as frontotemporal dementia (FTD) [23], dementia
with Lewy bodies (DLB) [24], and Parkinson’s dementia
(PD); [25] when MRI and laboratory tests (e.g., blood cell
counts, liver and renal function tests) did not support or
rule out a diagnosis of AD; and a history of alcoholism or
drug abuse.
Sample size






where S was the stand division and δ was the
allowable error. The planned sample size was generated
based on previous data obtained from an economic
evaluation of an AD-type dementia study [26]. Based on
the standard deviation (SD) of AD-related costs per pa-
tient per year (11,037) and an allowable error of 500, the
total sample size required was 1,872. Therefore, the
planned total sample size in this study was ~2,500 to
allow for a defective rate of 25%. Before starting the
study, information was surveyed from all randomly
selected participating sites, including the number of
dementia physicians at each site, the number of AD pa-
tients, and the proportion of outpatients and inpatients
in the last year. Based on these data 20–40 patients with
AD will be assigned for each site. The sites include hos-
pitals (Tier 3 hospitals, gerontology hospitals, mental
health centres and psychiatric hospitals), nursing homes,
gerocomiums, care facilities, and residences.
Cost classification
The AD-associated costs are defined as direct medical
costs, direct non-medical costs, and indirect costs (Table 1).
Direct medical costs
The direct medical costs include outpatient costs,
hospitalisation costs, and out-of-pocket expenses for
healthcare medications. Outpatient costs include the
reason for the visit (due to AD, AD-related symptoms,
or comorbidities), the number of outpatient visits in
the past 3 months, and the cost of the last clinic visit
in the same 3-months period. The cost of clinic visits
includes registration (general physicians or specialists),
diagnostic procedures (e.g., consultation, scale evaluation),
imaging (e.g., CT, MRI, SPECT, and PET), laboratory tests,
medication, and non-drug treatment (such as rehabilita-
tion treatment). The outpatient medication costs are di-
vided into three categories: anti-dementia drugs,
medications for the treatment of AD-related symptoms
(e.g., sleep disorders, psychiatric symptoms, and gastro-
intestinal symptoms caused by medications), and the
treatment of comorbidities. For anti-dementia drugs the
specific medications used and their corresponding costs
are also investigated. For comorbidity-associated costs, the
types of comorbidity and the associated costs are re-
corded. Investigations into the cost of hospitalisation in-
cluded the reason for hospitalisation (AD, AD-related
symptoms, or comorbidities), how many times a patient
was hospitalised in the past 12 months, and expenditures
on the last hospitalisation within the past 12 months. The
hospitalisation expenditure includes the cost of the ward
bed, formal care, examinations, laboratory tests, treat-
ment (such as rehabilitation, massage, and others),
and medications. The term “self-bought medications”
means that the patient or their caregivers purchased
the medications outside the hospital (out-of-pocket
spending). Questions include how many times medi-
cations were purchased in the past month and the
total expenditure during the same period. The above
data also include information regarding the patients’
payment method (including medical insurance for urban
workers or town residents, rural cooperative medical
insurance, commercial insurance and self-funded) and any
out-of-pocket expenses.
Direct non-medical costs
The direct non-medical costs include the cost of transpor-
tation, accommodation, and meals when visiting a phys-
ician, the cost of nourishment and healthcare equipment in
the patient’s daily life, and formal care fees. The cost of daily
nourishment, such as calcium, vitamin, protein powder,
and fish oil supplements, include the number of times
items were purchased and the amount spent in the last
12 months. The cost of healthcare equipment refers to
supplies, such as positioning watches, bracelets, and wheel-
chairs, used in the last 12 months. Formal care costs are
defined as the cost of nursing care given by professional
Table 1 Classification of AD-associated costs
AD-associated costs Subgroup costs
Direct medical cost outpatient
hospitalisation
out-of-pocket






Indirect cost informal care
intangible cost
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caregivers for patients in nursing homes/gerocomiums/care
facilities or at home, including the number of hours of care
and the average monthly expenses [27].
Indirect costs
Indirect costs include monetary loss caused by the
patients’ inability to work, reduction of informal care-
givers’ income, treatment of the mental suffering of
caregivers, and treatment of unexpected injuries in
AD patients or their caregivers. Because the AD
patients in this study are aged ≥ 60 years, most of whom
are retired as per China’s national regulations, their major
source of income is retirement pensions. Therefore, the
decrease in a patients’ income is not considered, because
it is independent of patients’ health status. Informal care-
givers are mostly the relatives or unpaid nonrelatives of
patients with no agency affiliation [28]. Investigation of
the informal caregivers include the length of time (hours)
provided by informal caregivers; the relationship between
the caregivers and AD patients; sex, age, and monthly job
losses for employed subjects (hours); and monthly salary.
Cost for the treatment of mental suffering of caregivers
refers to any symptoms triggered or worsened by taking
care of AD patients over the past 12 months. The
monetary loss caused by injuries to AD patients in-
cludes outpatient, examination, medication, transpor-
tation, and accommodation costs.
Others
To understand the relationship between AD costs and
other factors, parameters such as social demographics
and disease details are also investigated. The social
demographics include sex, age, education level, marital
status, occupation, salary, and the number of children.
The disease details include age at onset of AD, clinical
evaluations (based on ADL, GDS, MMSE and neuro-
psychiatric inventory [NPI] [29]), and comorbidities (e.g.,
stroke, diabetes, heart disease, hypertension, hyperlipid-
emia, lung diseases, cancer, arthritis, and other diseases
of the nervous system).
Data collection procedure
Electronic medical record systems are being used to identify
elderly patients diagnosed with AD among outpatients (in
the last 3 months), inpatients (in the last 12 months), those
living in urban residences and rural residences with their
families, and residents of nursing homes, gerocomiums, or
care facilities. The diagnosis of AD is re-confirmed by de-
mentia specialists before the start of the study. The inten-
sive dementia training program conducted in national and
regional centres included both theory and practice. It com-
prised the study methods, assessment of the scales and
internationally accepted diagnostic criteria of dementia and
its subtypes, neuroimaging (CT and MRI), and standard
procedures for diagnosis. Investigators are contacting
patients and re-confirm the accuracy of the AD diagnosis
according to the inclusion and exclusion criteria. Neuroim-
aging and laboratory tests will be performed when neces-
sary. New patients are also being enrolled during the study
period. Face-to-face questionnaires will be administered to
AD patients and their caregivers when the data and infor-
mation could not be collected through electronic medical
record or residence health systems. The surveys are being
administered by investigators to ensure the accuracy of the
diagnosis and data.
Measures
Total cost per patient per year
The total cost per patient per year is determined by
adding the annual direct medical costs, direct non-
medical costs, and indirect costs for each patient.
When calculating the cost of the recuperation fee
for patients who required nursing care in nursing
homes, gerocomiums, or care facilities, 8% of the
basic cost is subtracted to reflect the AD patient’s
basic cost of living [30]. Two approaches are being
used to estimate the monetary loss of informal caregivers.
For the informal caregivers who have no stable job before
taking care of the AD patients, the average labour market
income reported by each research centre is being
multiplied by the amount of time spent being a care-
giver to obtain the monetary loss. For individuals with
a stable job before taking care of the AD patient, the
monetary loss is being obtained by multiplying the
hourly salary before they stop working by the time
spent (hours) being a caregiver. All of the costs will be
converted into the average annual cost.
Current total number of patients with AD in China
A model is established to estimate the total number of
Chinese patients with AD in 2015 based on the litera-
ture. The total number of patients with AD is defined as
M and the percentage of AD patients who received anti-
dementia treatment is defined as d%. Therefore, the
number of anti-dementia treated patients (M1) is M ×
d%, and the number of patients not treated for dementia
(M2) is M × (1–d)%. Based on previous reports, the per-
centage of AD patients who are treated for dementia is
10–30% [31, 32]. Epidemiological studies have revealed
that the number of AD patients in China aged ≥ 60 years
in 1990, 2000, and 2010 was 1.93 million, 3.71 million,
and 5.69 million, respectively [8, 33, 34]. A linear regres-
sion model is used to estimate the age-specific preva-
lence of AD in 2015 by recording the prevalence of AD
among different-aged patients. By multiplying the
percentage of AD among elderly individuals aged ≥
60 years by the total national elderly population (aged ≥
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60 years) in 2015, we obtain the estimated total number
of AD patients of China, which is defined as M.
Per capita annual cost of AD patients (who accepted or did
not accept treatment)
The cost associated with treating dementia patients
(F1) is divided into two groups: “outpatient costs” and
“hospitalised or inpatient costs.” F1_1 is defined as the
average annual cost in the inpatient group (average
annual cost × the number of inpatients annually), and
F1_2 is the average annual cost in the outpatient group
(average annual cost × the number of outpatients an-
nually). Patients described as not accepting treatment
are those who did not select either “outpatient service
costs” or “hospitalised costs” in their questionnaire. F2
is defined as the average annual cost per AD patient
who did not accept treatment.
Nationwide cost due to AD
A pilot study is performed, which reveal that the average
annual ratio of inpatients to outpatients in different
hospitals is ~1:6. Hence, the number of patients who
undergo treatment nationwide (M1) is multiplied by 1/7
or 6/7 to obtain the number of hospitalised patients with
AD (M1_1) and the number of outpatients with AD
(M1_2), respectively. Thus, the total national annual cost
of patients who accept treatment is M1_1 × F1_1 +M1_2 ×
F1_2. M2 is defined as the number of patients who did
not accept treatment, and this value is multiplied by F2
to obtain the total annual national cost of patients who
do not accept treatment. Therefore, the total annual na-
tional cost of patients with AD is M1_1 x F1_1 +M1_2 x
F1_2 +M2 x F2. To estimate the costs attributable to AD,
generalised linear models (GLMs) related to coexisting
conditions (stroke, diabetes, heart disease, hypertension,
lung disease, cancer, arthritis, and psychiatric problems)
and demographics (sex, age, educational level, marital
status, and household income) are used. Moreover, we
estimate the total numbers of people who will be living
with AD in 2020, 2030, 2040, and 2050 to predict the
total annual cost of AD in future decades. Few large-
scale national surveys of the monetary cost or economic
burden of AD have been conducted in China, or indeed
in Asia. To remedy this lack of data, we also systematic-
ally review COI studies of AD that report annual costs
per patient. This will enable estimation of the proportion
of the global burden of AD costs faced by China.
Furthermore, it will enable comparison of the economic
burden of AD in developed and developing countries.
Statistical analysis
Descriptive statistics
Descriptive statistics (means ± SDs or frequencies) will be
used to summarise the patient characteristics, including
age, sex, years of formal education, time since AD diagno-
sis, marital status, living location (urban or rural), number
of children, baseline MMSE score, baseline ADL score,
number of comorbidities, number of caregivers, and infor-
mation about the caregivers (such as sex, age, relationship
to patient, and employment status). Mean values and
ranges will be also presented because cost data are
commonly positively skewed and the median cost could
be zero for highly skewed data.
Calculation of costs due to AD
Different distributions will be considered for the
monetary costs associated with AD, including normal,
lognormal, exponential, and gamma. To compare the
costs of different subgroups, t-tests or Kruskal-Wallis
analysis of variance will be used. For base case ana-
lyses, GLMs will be developed using the gamma distri-
bution with a log-link function [35]. Models will be
developed with the total cost per person per year as
the dependent variable, and independent variables will
be selected using a backward selection method (P >
0.05 for removal), with patient age, patient sex, and
MMSE severity all forced to remain in the model.
Considering the diverse of research centres sites, we
also added the sites as a covariant in the analysis. The
variables used for backward selection will be years of
formal education, time since AD diagnosis, marital
status, location of residence (urban or rural), number
of children, baseline MMSE score, baseline ADL score,
the number of caregivers, the number of comorbidi-
ties, and caregiver demographics.
Sensitivity analyses
Sensitivity analyses will be conducted to examine the
robustness of the results from the base case model and
explore correlations between certain factors that could
impact each other. First, the total costs of dementia will
be estimated using the prevalence rates derived from a
systematic review. Then the minimum and maximum
salaries (rather than the average) will be used to estimate
the relative costs. The total costs will be estimated by
assuming that 70 and 99% of patients with AD are living
at home, instead of 86% in the primary option. Further-
more, different costing caregiver time will be used to
estimate the total cost. All of the analyses will be per-
formed using R software version 3.2.3.
Quality control
The questionnaire and standard operating standards pro-
cedures were formulated based on previous studies and by
consulting relevant experts internationally and domestic-
ally. All of the staff working on this study were trained to
ensure that standard operating procedures were followed,
and all of them were required to pass an examination
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before beginning data collection. A pilot study was con-
ducted in five randomly selected hospitals and residences
to evaluate the feasibility and reliability of the question-
naire and to identify any potential problems.
Results
This study began in October 2015 and will finish in
March 2016. The main findings will be the per patient
and national annual monetary costs of AD in China. The
costs include direct medical, direct non-medical, and in-
direct costs. Data of the subgroup costs will also be re-
ported. Social demographics, illness and treatment of
AD, scale scores, and comorbidities will be shown in a
table at last.
Discussion
To the best of our knowledge, this is the first study
on AD cost that encompassed nearly all of the pro-
vincial, municipal, and autonomous regions in main-
land China. To complete this survey, it is crucial to
prepare a thoughtful and well-designed protocol. In
the study design phase, we referred to an international
popular survey method and adjusted it to China’s
national conditions. We also tested the protocol in a
pilot study; the results suggested that this protocol
can be used in China.
This protocol includes measures specific to problems
that exist in China. First, China has the largest popula-
tion of any country, and the varying economic develop-
ment among regions [36] might result in introduction of
bias. To avoid this, the study includes 30 of the 33 pro-
vincial, municipal, and autonomous regions in mainland
China. This ensures that both poor and rich areas are
covered to balance the gap between them because people
in poor areas may have more health problems [37].
Second, in China, hospitals with physicians for patients
with AD include Tier 3 general hospitals, gerontology
hospitals, mental health centres, psychiatric hospitals, and
other institutions such as nursing homes, gerocomiums,
and care facilities [36]. Therefore, all types of institutions
are included in the current investigation to ensure repre-
sentation of the diversity of AD costs among hospitals and
institutions. The hospitals and institutions are selected
randomly to reduce the test error. Third, the target popu-
lation of this survey is patients with AD. Accurate diagno-
sis of AD is required for calculation of the true monetary
cost of the condition. AD patients diagnosed according to
the NINCDS-ADRDA criteria are enrolled in the study. In
particular, to ensure accuracy, the diagnosis of patients
diagnosed with AD prior to the start of this study was re-
confirmed. In addition, the project team comprises a
group of dementia physicians, who are trained in the diag-
nostic processes for dementia and AD to guarantee the
quality and consistency of the diagnosis. Fourth, for
accurate determination of the costs associated with AD
patients, electronic records systems are used to deter-
mine the costs of all treatment items. This measure
guarantees the absence of error. Therefore, the current
protocol facilitates determination of the cost burden of
AD patients in China.
We carefully consider cost classifications for the total
cost of AD. Cost in the present study includes direct
medical costs, direct non-medical costs, and indirect
costs. The cost classification used was in accordance with
those that are commonly used internationally [11, 38].
This strategy is intended not only to ensure that the
results cover all aspects of costs for AD patients but also
to enable comparison with findings from developed
countries. In addition, the cost of AD includes both
AD patients and their caregivers. Our previous study
revealed that 84.9% of AD patients are cared for by
non-professional caregivers at home [39]. This is
because China faces a shortage of nursing homes, and
the Chinese tradition of filial piety mandates that
when they lose the ability to live independently,
patients should be cared for by their families. Therefore, it
is important to include caregivers in calculating AD costs.
These procedures are conducted to ensure the accuracy,
reliability, and credibility of data on AD in China.
Conclusion
In conclusion, this study provides an important basis for
calculation of the annual cost of AD, will assist the un-
derstanding of the government and policy makers of the
position and role of healthcare in the national economy
and social development, and will enable formulation of a
national plan for dementia. In addition, the results will
facilitate evaluation of the effectiveness of the national
funds allocated to AD research.
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